Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careValidation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care, Published online: 14 December 2017; doi:10.1038/s41408-017-0018-7Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research

Related Links:

(Washington University School of Medicine) A DNA-based analysis of blood cells soon after a stem cell transplant can predict likelihood of disease recurrence in patients with myelodysplastic syndrome (MDS), a group of cancerous disorders characterized by dysfunctional blood cells, according to new research at Washington University School of Medicine in St. Louis. Such a practice could help doctors identify patients at high risk of disease recurrence early after a transplant and help guide treatment decisions.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This article summarizes the milestones in the development of ivosidenib leading to this first approval in the USA for the treatment of patients with relapsed or refractory AML with a susceptibleIDH1 mutation. Clinical development for AML, cholangiocarcinoma, glioma, myelodysplastic syndromes and solid tumours is ongoing worldwide.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Cancer Science, EarlyView.
Source: Cancer Science - Category: Cancer & Oncology Authors: Source Type: research
(Cincinnati Children's Hospital Medical Center) Scientists may be on the road to solving the mystery of a group of mostly incurable blood diseases called myelodysplastic syndromes (MDS), which cause people to have immature, malfunctioning bone marrow cells that fuel a diverse set of health problems and can lead to leukemia. Researchers report in the journal Cancer Discovery identifying a gene that in laboratory experiments fuels the biological processes that cause the different types of MDS that physicians see in patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In this interview, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks about TP53-mutated myelodysplastic syndromes (MDS) and the results of the Phase Ib/II cl... Author: VJHemOnc Added: 08/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients with high risk myelodysplastic syndromes (MDS) to individ... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Bu... Author: VJHemOnc Added: 08/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L Abstract Myelodysplastic syndrome (MDS), a largely incurable hematological malignancy, is derived from aberrant clonal hematopoietic stem/progenitor cells (HSPCs) that persist after conventional therapies. Defining the mechanisms underlying MDS HSPC maintenance is critical for developing MDS therapy. The deacetylase SIRT1 regulates stem cell proliferation, survival, and self-renewal by deacetylating downstream proteins. Here we show that SIRT1 protein levels were downregulated in MDS HSPCs. Genetic or pharmacological activation of SIRT1 inhibited MDS HSPC functions, w...
Source: Cell Stem Cell - Category: Stem Cells Authors: Tags: Cell Stem Cell Source Type: research
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Stanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, Eunjung Jang, Esther Obeng, Sydney X. Lu, Bo Liu, Daichi Inoue, Akihide Yoshimi, Michelle Ki, Mirae Yeo, Xiao Jing Zhang, Min Kyung Kim, Hana Cho, Young Rock Chung, Justin Taylor, Benjamin H. Durham, Young Joon Kim, Alessandro Pastore, Sebastien MonetteSummaryMutations affecting RNA splicing factors are the most common genetic alterations in myelodysplastic syndrome (MDS) patients and occur in a mutually exclusive manner. The basis for the mutual exclusivity of these mutations and how they co...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome, Published online: 13 August 2018; doi:10.1038/s41408-018-0115-2The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Myelodysplastic Syndrome